Pharmenterprises LLC   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Moscow Russian Federation (2003)

Organization Overview

First Clinical Trial
2015
NCT03441815
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Pharmenterprises Biotech LLC | PHARMENTERPRISES LLC | RSV Therapeutics LLC

Active Ingredients

Drugs in Phase 3 Trials (3)

histamine (2 trials)

treamid (3 trials)

xc221 (5 trials)

Drugs in Phase 2 Trials (1)

xc8 (1 trial)

Drugs in Phase 1 Trials (2)

unifluvec (1 trial)

xc243 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Asthma (Phase 2)

Communicable Diseases (Phase 3)

Infections (Phase 3)

Influenza, Human (Phase 3)

Metabolic Syndrome (Phase 1)

Pneumonia (Phase 2)

Respiratory Tract Infections (Phase 3)

Virus Diseases (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 13
  • # of Trial APIs: 6